Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis

Nakamura, Yumejiro; Shimizu, Tomohiro; Asano, Tsuyoshi; Shimodan, Shun; Ishizu, Hotaka; Takahashi, Daisuke; Takahata, Masahiko; Iwasaki, Norimasa

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis

Nakamura, Yumejiro; Shimizu, Tomohiro; Asano, Tsuyoshi et al.

Journal of Bone and Mineral Metabolism, 2021, 39(5), 824-832

Permalink : https://hdl.handle.net/2115/86685

このアイテムのアクセス数:518件（2026-08-20 10:11 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JBMM s00774-021-01221-6	pdf	4.50 MB	408

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/86685
タイトル	Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
著者	Nakamura, Yumejiro ; Shimizu, Tomohiro ; Asano, Tsuyoshi ; Shimodan, Shun ; Ishizu, Hotaka ; Takahashi, Daisuke ; Takahata, Masahiko ; Iwasaki, Norimasa
著者名 Nakamura, Yumejiro
e-Rad_Researcher 60784246 著者名 Shimizu, Tomohiro
e-Rad_Researcher 50722493 著者名 Asano, Tsuyoshi
著者名 Shimodan, Shun
著者名 Ishizu, Hotaka
e-Rad_Researcher 90528845 著者名 Takahashi, Daisuke
e-Rad_Researcher 40374368 著者名 Takahata, Masahiko
e-Rad_Researcher 30322803 著者名 Iwasaki, Norimasa
言語	英語
キーワード	Postmenopausal osteoporosis
	Eldecalcitol
	Denosumab
	Zoledronic acid
	Bone metabolic marker
発行日	2021-09
出版者	Springer
収録物名	Journal of Bone and Mineral Metabolism
巻(号)	39(5)
ページ	824-832
抄録	Introduction We aimed to compare the efficacy after switching from either bisphosphonates (BPs) or non-BPs (NBPs) to combination therapies of denosumab (DMAb) or zoledronic acid (Zol) with eldecalcitol (ELD) in bone mineral density (BMD) and bone metabolism and investigate the prognostic and risk factors of side effects of this therapy. Materials and methods One-hundred forty-eight patients with postmenopausal osteoporosis were recruited; their therapy was switched from BPs or NBPs to Zol or DMAb plus ELD (BP-Zol: 43, NBP-Zol: 32, BP-DMAb: 35, and NBP-DMAb: 38). Longitudinal changes in bone metabolic markers (P1NP and TRACP-5b) and BMD were evaluated. Results In the BP-Zol group, P1NP did not change after 6 months and increased by 38.9% after 12 months. TRACP-5b decreased 15.8% after 6 months, but came back to baseline values 12 months after administration. In the rest of the groups, the bone metabolic markers remained suppressed after 6 and 12 months. Compared with baseline, all groups showed increase in BMD after 6 and 12 months. Bone metabolic markers at baseline were correlated with %change in lumbar spine BMD from baseline to 12 months. P1NP and 25-hydroxy vitamin D levels at baseline were identified as potential predictors of development of acute-phase reactions. Conclusions The combination therapy of Zol or DMAb and ELD may increase BMD at 12 months after the first administration in Japanese patients with postmenopausal osteoporosis, regardless of BPs pretreatment. Bone metabolic markers at baseline may be useful predictors for reaction to the therapy and side effects caused by these combination therapies in postmenopausal osteoporosis.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a post-peer-review, pre-copyedit version of an article published in Journal of Bone and Mineral Metabolism. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00774-021-01221-6
PISSN	0914-8779
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00774-021-01221-6